Drug Profile
Research programme: Src-family kinase inhibitors - Systems Medicine
Alternative Names: SMi 813; SMi 829Latest Information Update: 09 Mar 2010
Price :
$50
*
At a glance
- Originator Systems Medicine
- Class Pyrimidines
- Mechanism of Action Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 Jul 2008 Preclinical development is ongoing
- 02 Nov 2007 Preclinical trials in Cancer in USA (unspecified route)